.Attributes Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean follow-up of 11 months, people with metastatic intestinal growths who obtained biomarker-matched treatments based on distributing lump DNA profiling revealed a greater medical advantage than those getting incomparable treatment.